<?xml version="1.0" encoding="UTF-8"?>
<p>Human infection by North American strains of EEEV is thought to be frequently asymptomatic, with some reports estimating that up to 96% percent of patients demonstrate no symptoms of infection [
 <xref rid="B17-microorganisms-08-01167" ref-type="bibr">17</xref>,
 <xref rid="B64-microorganisms-08-01167" ref-type="bibr">64</xref>,
 <xref rid="B67-microorganisms-08-01167" ref-type="bibr">67</xref>,
 <xref rid="B68-microorganisms-08-01167" ref-type="bibr">68</xref>,
 <xref rid="B69-microorganisms-08-01167" ref-type="bibr">69</xref>,
 <xref rid="B70-microorganisms-08-01167" ref-type="bibr">70</xref>]. In patients who will demonstrate symptoms, a 4–10-day prodromal phase follows the bite of an infected mosquito, characterized primarily by nonspecific symptoms, including but not limited to fever, chills, malaise, and myalgia. This nondescript febrile illness can either resolve, or progress to encephalitic disease characterized by fever, headaches, nausea, vomiting, diarrhea, altered mental status, seizures, and coma [
 <xref rid="B17-microorganisms-08-01167" ref-type="bibr">17</xref>,
 <xref rid="B68-microorganisms-08-01167" ref-type="bibr">68</xref>,
 <xref rid="B71-microorganisms-08-01167" ref-type="bibr">71</xref>,
 <xref rid="B72-microorganisms-08-01167" ref-type="bibr">72</xref>]. Despite its low apparent:inapparent ratio of 1:23 [
 <xref rid="B64-microorganisms-08-01167" ref-type="bibr">64</xref>,
 <xref rid="B70-microorganisms-08-01167" ref-type="bibr">70</xref>,
 <xref rid="B72-microorganisms-08-01167" ref-type="bibr">72</xref>], symptomatic infection is associated with high mortality rates, with estimates of between 30–70% depending on the outbreak [
 <xref rid="B17-microorganisms-08-01167" ref-type="bibr">17</xref>,
 <xref rid="B64-microorganisms-08-01167" ref-type="bibr">64</xref>,
 <xref rid="B67-microorganisms-08-01167" ref-type="bibr">67</xref>,
 <xref rid="B68-microorganisms-08-01167" ref-type="bibr">68</xref>,
 <xref rid="B71-microorganisms-08-01167" ref-type="bibr">71</xref>,
 <xref rid="B72-microorganisms-08-01167" ref-type="bibr">72</xref>,
 <xref rid="B73-microorganisms-08-01167" ref-type="bibr">73</xref>], and up to 50% of survivors demonstrating serious neurological sequelae such as intellectual impairments, psychiatric manifestations, seizure disorders and nervous palsies [
 <xref rid="B68-microorganisms-08-01167" ref-type="bibr">68</xref>,
 <xref rid="B73-microorganisms-08-01167" ref-type="bibr">73</xref>,
 <xref rid="B74-microorganisms-08-01167" ref-type="bibr">74</xref>,
 <xref rid="B75-microorganisms-08-01167" ref-type="bibr">75</xref>,
 <xref rid="B76-microorganisms-08-01167" ref-type="bibr">76</xref>,
 <xref rid="B77-microorganisms-08-01167" ref-type="bibr">77</xref>,
 <xref rid="B78-microorganisms-08-01167" ref-type="bibr">78</xref>]. Anatomically, EEEV infection is particularly associated with lesions in the basal ganglia and thalamus based on MRI and/or CT imaging, although brain stem lesions have also been described [
 <xref rid="B79-microorganisms-08-01167" ref-type="bibr">79</xref>]. There is some evidence to suggest that symptomatic infection by EEEV is more fatal in adults than children, although surviving adults demonstrate milder sequelae [
 <xref rid="B64-microorganisms-08-01167" ref-type="bibr">64</xref>,
 <xref rid="B72-microorganisms-08-01167" ref-type="bibr">72</xref>,
 <xref rid="B73-microorganisms-08-01167" ref-type="bibr">73</xref>,
 <xref rid="B80-microorganisms-08-01167" ref-type="bibr">80</xref>]. In stark contrast, MADV (reported in the literature as SA EEEV until 2015) has historically been considered an equine pathogen [
 <xref rid="B64-microorganisms-08-01167" ref-type="bibr">64</xref>,
 <xref rid="B72-microorganisms-08-01167" ref-type="bibr">72</xref>,
 <xref rid="B81-microorganisms-08-01167" ref-type="bibr">81</xref>]. Indeed, until an outbreak taking place in Panama in 2010, MADV has been associated with only two cases of fatal human disease, one taking place in Brazil in 1956, and the other in Trinidad in 1972 [
 <xref rid="B82-microorganisms-08-01167" ref-type="bibr">82</xref>,
 <xref rid="B83-microorganisms-08-01167" ref-type="bibr">83</xref>,
 <xref rid="B84-microorganisms-08-01167" ref-type="bibr">84</xref>,
 <xref rid="B85-microorganisms-08-01167" ref-type="bibr">85</xref>]. Seven confirmed human patients were characterized over the course of the 2010 Panama outbreak, with only one reported fatality, which was not confirmed to be MADV). All seven patients progressed to neurologic disease, with six of the seven demonstrating seizures that progressed to status epilepticus (86% vs. 25% observed in North American outbreak) [
 <xref rid="B79-microorganisms-08-01167" ref-type="bibr">79</xref>,
 <xref rid="B85-microorganisms-08-01167" ref-type="bibr">85</xref>]. Imaging analyses also demonstrated differences from EEEV, with temporal lobe lesions observed as opposed to the characteristic basal ganglia and thalamic lesions previously reported [
 <xref rid="B79-microorganisms-08-01167" ref-type="bibr">79</xref>,
 <xref rid="B85-microorganisms-08-01167" ref-type="bibr">85</xref>]. Serosurveys conducted in endemic regions of Peru and Panama have demonstrated that 2 to 5% of the human population in these areas have had prior exposure to MADV, suggesting a high rate of asymptomatic or subclinical infections [
 <xref rid="B39-microorganisms-08-01167" ref-type="bibr">39</xref>,
 <xref rid="B84-microorganisms-08-01167" ref-type="bibr">84</xref>,
 <xref rid="B85-microorganisms-08-01167" ref-type="bibr">85</xref>].
</p>
